The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormonerefractory prostate cancer (HRPCA)
| dc.creator | Mitsogiannis, I. | en |
| dc.creator | Oeconomou, A. | en |
| dc.creator | Gravas, S. | en |
| dc.creator | Mitrakas, L. | en |
| dc.creator | Tzortzis, V. | en |
| dc.creator | Moutzouris, G. | en |
| dc.creator | Melekos, M. | en |
| dc.date.accessioned | 2015-11-23T10:39:48Z | |
| dc.date.available | 2015-11-23T10:39:48Z | |
| dc.date.issued | 2007 | |
| dc.identifier | 10.1016/s1569-9056(07)60312-1 | |
| dc.identifier.issn | 1569-9056 | |
| dc.identifier.uri | http://hdl.handle.net/11615/31092 | |
| dc.source | European Urology Supplements | en |
| dc.source.uri | <Go to ISI>://WOS:000244422600314 | |
| dc.subject | Urology & Nephrology | en |
| dc.title | The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormonerefractory prostate cancer (HRPCA) | en |
| dc.type | journalArticle | en |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||